应用体外化疗药物敏感检测技术指导卵巢肿瘤个体化化疗的可行性研究

目的:探讨应用ATP-肿瘤化学敏感检测(ATP-TCA)技术指导卵巢肿瘤患者的临床个体化化疗的可行性。方法:采用ATP-TCA法检测11例卵巢肿瘤手术标本对8种联合化疗方案的敏感性。结果:11例标本中有10例成功进行了ATP-TCA检测,ATP-TCA的可评价率为91%;所测标本的体外敏感率较高的是:DDP+ADM、PTX+DDP、VCR+ACTD、DDP+VCR+BLM、PTX+CBP,强敏感率均达60%以上;上皮性卵巢癌最为敏感化疗方案的是CAP,其体外有效率达83.3%(5/6)。结论:ATP-TCA法是一种敏感、客观的肿瘤药敏检测技术,是开展卵巢肿瘤个体化化疗的一种重要的体外药物筛选方法。

Study on the feasibility of individual chemotherapy for ovarian neoplasms directed by chemosensitivity assay in vitro

Objective:To explore the feasibility of clinical individual chemotherapy for the patients with ovarian neoplasms by ATP-tumor chemosensitivity assay(ATP-TCA).Methods:ATP-TCA was used to detect the sensitivities of 11 samples of ovarian neoplasms after surgery to 8 kinds of combined chemotherapy regimens.Results:Among 11 samples,10 samples received ATP-TAC detection successfully,the evaluability rate was 91%.The chemotherapy regimens with high sensitive rates in vitro included DDP+ADM,PTX+DDP,VCR+ACTD,DDP+VCR+BLM,and PTX+CBP,the sensitive rates were more than 60%;epithelial ovarian cancer was sensitive to CAP regimen,the effective rate in vitro was 83.3%(5/6).Conclusion:ATP-TCA is a sensitive and objective method for the evaluation of tumor chemosensitivity,and it is an important method for in vitro screening of chemotherapeutic drugs during individual chemotherapy of ovarian neoplasms.